3 days popular7 days popular1 month popular3 months popular

In prostate cancer patients carrying ‘BRCA’ mutations, conventional therapies are less efficient

patients carrying inherited mutations in the BRCA genes respond less well to , including surgery and/or radiotherapy – and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal , points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients.

[CNIO Table]
This table shows 3-, 5- and 10-year metastasis-free survival according to the treatment and presence of .
Credit: CNIO


The study has been financed by the Ronald and Rita McAulay Foundation, the , the Spanish Association against Cancer (AECC), the GAME-ON initiative, and the European Union.

Reference article:

Effect of BRCA mutations on metatastatic relapse and cause-specific survival after radical treatment for localized prostate cancer. Elena Castro, Chee Goh, Daniel Leongamornlert, Ed Saunders, , Tokhir Dadaev, Koveela Govindasami, Michelle Guy, Steve Ellis, Debra Frost, Elizabeth Bancroft, Trevor Cole , Marc Tischkowitz, M. John Kennedy, Jacqueline Eason, Carole Brewer, D. Gareth Evans, Rosemarie Davidson, Diana Eccles, Mary E. Porteous, Fiona Douglas, Julian Adlard, Alan Donaldson, Antonis C. Antoniou, Zsofia Kote-Jarai, Douglas F. Easton, David Olmos, Rosalind Eeles. European Urology (2014). doi: 10.1016/j.eururo.2014.10.022

Centro Nacional de Investigaciones Oncologicas (CNIO)